FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
FR901228 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
to grow and by blocking blood flow to the cancer. This phase II trial is studying how well
FR901228 works in treating patients with relapsed or refractory non-Hodgkin's lymphoma.